4000-520-616
欢迎来到免疫在线!(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
主营:主营:分子类,蛋白类,抗体类,生化类试剂
咨询热线电话
4000-520-616
当前位置: 首页 > 产品中心 > Functional_antibody > Millipore/04-244 | Anti-phospho-p53 (Ser392) Antibody, clone EP155Y, rabbit monoclonal/04-244/100 µL
商品详细Millipore/04-244 | Anti-phospho-p53 (Ser392) Antibody, clone EP155Y, rabbit monoclonal/04-244/100 µL
Millipore/04-244 | Anti-phospho-p53 (Ser392) Antibody, clone EP155Y, rabbit monoclonal/04-244/100 µL
Millipore/04-244 | Anti-phospho-p53 (Ser392) Antibody, clone EP155Y, rabbit monoclonal/04-244/100 µL
商品编号: 04-244
品牌: 密理博
市场价: ¥0.00
美元价: 0.00
产地: 美国(厂家直采)
公司:
产品分类: 功能性抗体
公司分类: Functional_antibody
联系Q Q: 3392242852
电话号码: 4000-520-616
电子邮箱: info@ebiomall.com
商品介绍
Description
CatalogueNumber04-244
DescriptionAnti-phospho-p53(Ser392)Antibody,cloneEP155Y,rabbitmonoclonal
AlternateNames
  • AntigenNY-CO-13
  • Phosphoproteinp53
  • Tumorsuppressorp53
  • p53antigen
  • p53transformationsuppressor
  • p53tumorsuppressor
  • transformation-relatedprotein53
  • tumorproteinp53
BackgroundInformationThep53geneismutatedinapproximatelyhalfofallhumancancers.Itisinvolvedinthecellularresponsetocytotoxicstresses,andtogetherwithp19ARF,inducesexpressionofp21Cip1,tocausecellcyclearrest.Inaddition,p53isabletoinduceapoptosis,bothbytranscriptionalandnon-transcriptionalmechanisms.Theamino-terminal83aminoacidsofp53containthetransactivationdomain,aswellastheregioninvolvedintranscription-independentgrowthsuppression.Thecarboxy-terminalregioncontainstheDNA-bindingdomain,whichisregulatedbythreephosphorylationevents,andpotentiallybyacetylationalso.
ProductInformation
FormatUnpurified
PresentationUnpurifiedrabbitmonoclonalIgGinbuffercontaining50mMTris-Glycine(pH7.4),0.15MNaCl,40%Glycerol,0.01%sodiumazideand0.05%BSA.
StorageandShippingInformation
StorageConditionsStablefor1yearat-20ºCfromdateofreceipt.
HandlingRecommendations:Uponreceipt,andpriortoremovingthecap,centrifugethevialandgentlymixthesolution.Aliquotintomicrocentrifugetubesandstoreat-20°C.Avoidrepeatedfreeze/thawcycles,whichmaydamageIgGandaffectproductperformance.Note:VariABIlityinfreezertemperaturesbelow-20°Cmaycauseglycerolcontainingsolutionstobecomefrozenduringstorage.
Applications
ApplicationUseAnti-phospho-p53(Ser392)Antibody,cloneEP155Y(rabbitmonoclonalantibody)validatedinIHC(P),ICC,IP,WBtodetectphospho-p53(Ser392)alsoknownasAntigenNY-CO-13,Phosphoproteinp53,Tumorsuppressorp53,p53antigen.
KeyApplications
  • Immunohistochemistry(Paraffin)
  • Immunocytochemistry
  • Immunoprecipitation
  • WesternBlotting
ApplicationNotesImmunohistochemistry(Paraffin)Analysis:
Anti-phospho-p53(Ser392)wasdilutedto1:200.


ImmunofluorescentImmunocytochemistry:
Cellswerestainedwithanti-phopsho-p53(Ser392)ata1:250dilution.

Immunoprecipitation:
A1:50dilutionofapreviouslotwasusedinIP.
BIOLOGicalInformation
ImmunogenSyntheticpeptidecorrespondingtophosphorylatedSer392andsurroundingaminoacidsofhumanp53.
EpitopePhosphorylatedSer392
CloneEP155Y
HostRabbit
SpecificityThisantibodyrecognizesp53whenphosphorylatedonSer392.
IsotypeIgG
SpeciesReactivity
  • Human
  • Rat
SpeciesReactivityNoteProventoreactwithHumanandRat.
AntibodyTypeMonoclonalAntibody
EntrezGeneNumber
EntrezGeneSummaryThisgeneencodestumorproteinp53,whichrespondstodiversecellularstressestoregulatetargetgenesthatinducecellcyclearrest,apoptosis,senescence,DNArepair,orchangesinmetabolism.p53proteinisexpressedatlowlevelinnormalcellsandatahighlevelinavarietyoftransformedcelllines,whereit"sbelievedtocontributetotransformationandmalignancy.p53isaDNA-bindingproteincontainingtranscriptionactivation,DNA-binding,andoligomerizationdomains.Itispostulatedtobindtoap53-bindingsiteandactivateexpressionofdownstreamgenesthatinhibitgrowthand/orinvasion,andthusfunctionasatumorsuppressor.Mutantsofp53thatfrequentlyoccurinanumberofdifferenthumancancersfailtobindtheconsensusDNAbindingsite,andhencecausethelossoftumorsuppressoractivity.Alterationsofthisgeneoccurnotonlyassomaticmutationsinhumanmalignancies,butalsoasgermlinemutationsinsomecancer-pronefamilieswithLi-Fraumenisyndrome.Multiplep53variantsduetoalternativepromotersandmultiplealternativesplicinghavebeenfound.Thesevariantsencodedistinctisoforms,whichcanregulatep53transcriptionalactivity.[providedbyRefSeq].
GeneSymbol
  • FLJ92943
  • LFS1
  • P53
  • TRP53
  • p53
Modifications
  • Phosphorylation
PurificationMethodUnpurified
UniProtNumber
UniProtSummaryFUNCTION:Actsasatumorsuppressorinmanytumortypes;inducesgrowtharrestorapoptosisdependingonthephysiologicalcircumstancesandcelltype.Involvedincellcycleregulationasatrans-activatorthatactstonegativelyregulatecelldivisionbycontrollingasetofgenesrequiredforthisprocess.Oneoftheactivatedgenesisaninhibitorofcyclin-dependentkinases.ApoptosisinductionseemstobemediatedeitherbystimulationofBAXandFASantigenexpression,orbyrepressionofBcl-2expression.Ref.48

CofactorBinds1zincionpersubunit.

SUBUNITSTRUCTURE:InteractswithAXIN1.ProbablypartofacomplexconsistingofTP53,HIPK2andAXIN1Bysimilarity.BindsDNAasahomotetramer.InteractswithhistoneacetyltransferasesEP300andmethyltransferasesHRMT1L2andCARM1,andrecruitsthemtopromoters.Invitro,theinteractionofTP53withcancer-associated/HPV(E6)viralproteinsleadstoubiquitinationanddegradationofTP53givingapossIBLemodelforcellgrowthregulation.Thiscomplexformationrequiresanadditionalfactor,E6-AP,whichstablyassociateswithTP53inthepresenceofE6.C-terminusinteractswithTAF1,whenTAF1ispartoftheTFIIDcomplex.InteractswithING4andthisinteractionmaybeindirect.FoundinacomplexwithCABLES1andTP73.InteractswithHIPK1,HIPK2,andP53DINP1.InteractswithWWOX.MayinteractswithHCVcoreprotein.InteractswithUSP7andSYVN1.InteractswithHSP90AB1.InteractswithCHD8,leADIngtorecruithistoneH1andpreventtransactivationactivityBysimilarity.InteractswithARMC10,BANP,CDKN2AIPandE4F1.

SUBCELLULARLOCATION:Cytoplasm.Nucleus.Endoplasmicreticulum.Note=InteractionwithBANPpromotesnuclearlocalization.Ref.51Ref.56

DOMAIN:Thenuclearexportsignalactsasatranscriptionalrepressiondomain.Ref.34

PTM:Acetylated.AcetylationofLys-382byCREBBPenhancestranscriptionalactivity.DeacetylationofLys-382bySIRT1impairsitsabilitytoinduceproapoptoticprogramandmodulatecellsenescence.

PhosphorylationonSerresiduesmediatestranscriptionalactivation.PhosphorylatedbyHIPK1Bysimilarity.PhosphorylationatSer-9byHIPK4increasesrepressionactivityonBIRC5promoter.PhosphorylatedonThr-18byVRK1,whichmaypreventtheinteractionwithMDM2.PhosphorylatedonThr-55byTAF1,whichpromotesMDM2-mediateddegradation.PhosphorylatedonSer-46byHIPK2uponUVirradiation.PhosphorylationonSer-46isrequiredforacetylationbyCREBBP.PhosphorylatedonSer-392followingUVbutnotgammairradiation.PhosphorylateduponDNAdamage,probablybyATMorATR.PhosphorylatedonSer-15uponultravioletirradiation;whichisenhancedbyinteractionwithBANP.

DephosphorylatedbyPP2A.SV40smallTantigeninhibitsthedephosphorylationbytheACformofPP2A.Ref.51Ref.24Ref.26Ref.31Ref.35Ref.36Ref.40Ref.41Ref.49Ref.53Ref.58Ref.59Ref.60

MaybeO-glycosylatedintheC-terminalbasicregion.StudiedinEB-1cellline.Ref.28

UbiquitinatedbySYVN1,whichleadstoproteasomaldegradation.Ref.56

MonomethylatedatLys-372bySETD7,leadingtostabilizeitandincreasetranscriptionalactivation.MonomethylatedatLys-370bySMYD2,leadingtodecreaseDNA-bindingactivityandsubsequenttranscriptionalregulationactivity.Lys-372monomethylationpreventstheinteractionwithSMYD2andsubsequenctmonomethylationatLys-370.Ref.50Ref.54Ref.55

DISEASE:TP53isfoundinincreasedamountsinawidevarietyoftransformedcells.TP53isfrequentlymutatedorinactivatedinabout60%ofcancers.

DefectsinTP53areinvolvedinesophagealsquamouscellcarcinoma(ESCC)[MIM:133239].ESCCisatumoroftheesophagus.

DefectsinTP53areacauseofLi-Fraumenisyndrome(LFS)[MIM:151623].LFSisanautosomaldominantfamilialcancersyndromethatinitsclassicformisdefinedbytheexistenceofaprobandaffectedbyasarcomabefore45yearswithafirstdegreerelativeaffectedbyanytumorbefore45yearsandanotherfirstdegreerelativewithanytumorbefore45yearsorasarcomaatanyage.OtherclinicaldefinitionsforLFShavebeenproposed(Ref.95andRef.98)andcalledLi-Fraumenilikesyndrome(LFL).Inthesefamiliesaffectedrelativesdevelopadiversesetofmalignanciesatunusuallyearlyages.Fourtypesofcancersaccountfor80%oftumorsoccurringinTP53germlinemutationcarriers:breastcancers,softtissueandbonesarcomas,braintumors(astrocytomas)andadrenocorticalcarcinomas.Lessfrequenttumorsincludechoroidplexuscarcinomaorpapillomabeforetheageof15,rhaBDomyosarcomabeforetheageof5,leukemia,Wilmstumor,malignantphyllodestumor,colorectalandgastriccancers.Ref.74Ref.75Ref.76Ref.77Ref.78Ref.97Ref.99Ref.104Ref.105

DefectsinTP53maybeassociatedwithnasopharyngealcarcinoma[MIM:161550];alsoknownasnasopharyngealcancer.

DefectsinTP53arefoundinBarrettmetaplasia;alsoknownasBarrettesophagus.Itisaconditioninwhichthenormallystratifiedsquamousepitheliumoftheloweresophagusisreplacedbyametaplasticcolumnarepithelium.Theconditiondevelopsasacomplicationinapproximately10%ofpatientswithchronicgastroesophagealrefluxdiseaseandpredisposestothedevelopmentofesophagealadenocarcinoma.

DefectsinTP53areinvolvedinheadandnecksquamouscellcarcinomas(HNSCC)[MIM:275355].

DefectsinTP53areinvolvedinoralsquamouscellcarcinoma(OSCC).Cigarettesmokeisaprimemutagenicagentincanceroftheaerodigestivetract.

DefectsinTP53areacauseoflungcancer[MIM:211980].

DefectsinTP53areacauseofchoroidplexuspapilloma[MIM:260500].Choroidplexuspapillomaisaslow-growingbenigntumorofthechoroidplexusthatofteninvadestheleptomeninges.Inchildrenitisusuallyinalateralventriclebutinadultsitismoreofteninthefourthventricle.Hydrocephalusiscommon,eitherfromobstructionorfromtumorsecretionofcerebrospinalfluid.Ifitundergoesmalignanttransformationitiscalledachoroidplexuscarcinoma.Primarychoroidplexustumorsarerareandusuallyoccurinearlychildhood.Ref.108

DefectsinTP53areacauseofoneformofhereditaryadrenocorticalcarcinoma(ADCC)[MIM:202300].ADCCisararechildhoodtumor,representingabout0.4%ofchildhoodtumors,withahighincidenceofassociatedtumors.ADCCoccurswithincreasedfrequencyinpatientswiththeBeckwith-Wiedemannsyndrome[MIM:130650]andisacomponenttumorinLi-Fraumenisyndrome[MIM:151623].Ref.107

SIMILARITY:Belongstothep53family.

MolecularWeight53kDa
PhysicochemicalInformation
Dimensions
MaterialsInformation
MaterialsInformation
品牌介绍
密理博(Millipore)公司成立于1954年,总部位于美国麻省,在全世界设有47个办事处,为100多个国家提供产品和技术服务。目前全球雇员超过5800人,在美国、法国和日本等国家拥有7家大型生产工厂,主要生产过滤膜及膜过滤产品。20世纪80年代,密理博公司进入中国市场。先后在香港、北京、上海、广州及成都设立了办事机构,并于2000年4月在上海浦东外高桥保税区建立了密理博(上海)贸易有限公司。为了更好地满足中国用户的需求,密理博中国主页于2006年11月向广大用户开放,介绍密理博中国有限公司的最新动态,力求为用户打造专业的产品与服务信息交流平台。